TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board
08 Mayo 2024 - 4:00AM
Business Wire
TOLREMO therapeutics AG (TOLREMO) today announced the
appointment of Alan Sandler, M.D., to its Scientific Advisory Board
(SAB). Dr. Sandler, a leading expert in oncology research and
pharmaceutical development, was most recently Chief Medical Officer
at Mirati Therapeutics, which was acquired by Bristol Myers Squibb
in 2024. He joins the SAB as an important addition to TOLREMO’s
internal resources to support the development of an innovative
approach to preventing transcriptional cancer drug resistance. The
company’s lead candidate, TT125-802, is a small molecule CBP/p300
bromodomain inhibitor currently advancing through a Phase 1
clinical trial.
“Alan brings extensive experience in drug development, including
clinical development experience with one of the leading KRAS
inhibitors,” said Stefanie Flückiger-Mangual, PhD, Co-founder
and Chief Executive Officer of TOLREMO. “We welcome his
insights as we make important progress toward delivering a novel
therapeutic solution to addressing resistance to targeted cancer
therapies.”
“I have been impressed with TOLREMO’s work. The team has
discovered an exciting pivotal mechanism that governs critical
transcriptional resistance pathways,” said Alan Sandler, M.D.,
Scientific Advisory Board member at TOLREMO. “Over the course
of my career, I have seen the need for an innovative approach to
address this form of drug resistance, and I look forward to
supporting the development of TT125-802 as a backbone for
resistance-preventing combination therapies.”
Dr. Alan Sandler is a distinguished leader in oncology and drug
development with extensive experience in both industry and
academia. His expertise spans clinical development and operations,
regulatory affairs, drug safety and development strategies. Dr.
Sandler previously held the position of Executive Vice President,
Chief Medical Officer at Mirati Therapeutics, a Bristol Myers
Squibb company. Before joining Mirati, he was the President, Global
Head of Development in Oncology at Zai Lab. Prior to that, Dr.
Sandler held roles of progressive responsibility at Genentech, a
member of the Roche Group, where he ultimately served as Senior
Vice President and Global Head, Product Development of Oncology
Solid Tumors. His academic positions include roles at Oregon Health
and Science University, where he served as Professor of Medicine
and Head of the Division of Hematology/Medical Oncology; Vanderbilt
University as an Associate Professor of Medicine; and Indiana
University as Assistant Professor of Medicine. Dr. Sandler earned
his M.D. from Rush Medical College and completed his training in
internal medicine and a fellowship in medical oncology at Yale-New
Haven Medical Center. An active contributor to the medical field,
he has authored over 300 publications, including peer-reviewed
articles, reviews, abstracts, and book chapters.
About TOLREMO
TOLREMO therapeutics' mission is to prevent non-genetic cancer
drug resistance by dismantling the earliest defense to targeted
therapies. Led by phenotypic insights, we discovered a pivotal
mechanism that governs critical transcriptional resistance
pathways. Our clinical compound TT125-802 is an orally available
small molecule inhibitor designed to block these survival
techniques to significantly improve the response rates and
durability of established treatments. By stopping cancer drug
resistance as it emerges, we aim to surmount a universal challenge
for current and future targeted therapies for lasting patient
benefit.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240508482286/en/
TOLREMO therapeutics AG Dr. Stefanie Flückiger-Mangual, CEO and
co-founder stefanie.flueckiger@tolremo.com Trophic Communications
Dr. Alison Opalko or Gretchen Schweitzer +49 151 54041130 or +49
172 861 8540 tolremo@trophic.eu